Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability

PURPOSE: Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lipid A, 3D-PHAD® adjuvant. METHODS: Virosomes were initially formed by contacting a lipid film containing 3D-PHAD® w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lederhofer, J., van Lent, J., Bhoelan, F., Karneva, Z., de Haan, A., Wilschut, J.C., Stegmann, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061504/
https://www.ncbi.nlm.nih.gov/pubmed/29971500
http://dx.doi.org/10.1007/s11095-018-2453-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061504/
https://www.ncbi.nlm.nih.gov/pubmed/29971500
http://dx.doi.org/10.1007/s11095-018-2453-y

Ejemplares similares